Showing results (181-190 of 276) with videos related to
Sort By:
Pageof 28
European Heart Journal|February 8, 2003
Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-makingL K Newby, V Hasselblad, P W Armstrong, et al.Journal of the American College of Cardiology|August 1, 1993
Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapyF Van de Werf, L Janssens, T Brzostek, et al.Journal of the American College of Cardiology|May 1, 1992
Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering CommitteeE J Topol, P Armstrong, F Van de Werf, et al.Circulation|January 13, 1999
Functional recovery of subepicardial myocardial tissue in transmural myocardial infarction after successful reperfusion: an important contribution to the improvement of regional and global left ventricular functionJ Bogaert, A Maes, F Van de Werf, et al.Circulation|July 1, 1992
Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study GroupA E Arnold, M L Simoons, F Van de Werf, et al.The Biochemical Journal|November 1, 1989
Phospholipid-protein interactions of the plasma-membrane Ca2+-transporting ATPase. Evidence for a tissue-dependent functional differenceL Missiaen, L Raeymaekers, F Wuytack, et al.The American Journal of Cardiology|November 15, 1989
Effect of intravenous diltiazem on myocardial ischemia occurring during percutaneous transluminal coronary angioplastyJ Piessens, T Brzostek, F Stammen, et al.Klinische Wochenschrift|January 1, 1988
[Randomized double-blind study comparing tissue-type plasminogen activator with placebo in acute myocardial infarct]W Bleifeld, M Verstraete, R W Brower, et al.American Heart Journal|June 1, 1990
Evaluation of the effect of thrombolytic treatment on infarct size and left ventricular function by enzymatic, scintigraphic, and angiographic methods. The European Cooperative Study Group for Recombinant Tissue Type Plasminogen ActivatorL Mortelmans, J Vanhaecke, E Lesaffre, et al.Heart (British Cardiac Society)|March 19, 2005
Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trialR C Welsh, W Chang, P Goldstein, et al.Pageof 28